IL136376A0 - Transdermal estrogen agonist-antagonist therapy - Google Patents

Transdermal estrogen agonist-antagonist therapy

Info

Publication number
IL136376A0
IL136376A0 IL13637600A IL13637600A IL136376A0 IL 136376 A0 IL136376 A0 IL 136376A0 IL 13637600 A IL13637600 A IL 13637600A IL 13637600 A IL13637600 A IL 13637600A IL 136376 A0 IL136376 A0 IL 136376A0
Authority
IL
Israel
Prior art keywords
estrogen agonist
antagonist therapy
transdermal estrogen
transdermal
estrogen
Prior art date
Application number
IL13637600A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL136376A0 publication Critical patent/IL136376A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
IL13637600A 1999-06-01 2000-05-25 Transdermal estrogen agonist-antagonist therapy IL136376A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13716499P 1999-06-01 1999-06-01

Publications (1)

Publication Number Publication Date
IL136376A0 true IL136376A0 (en) 2001-06-14

Family

ID=22476088

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13637600A IL136376A0 (en) 1999-06-01 2000-05-25 Transdermal estrogen agonist-antagonist therapy

Country Status (16)

Country Link
EP (1) EP1057480B1 (de)
JP (1) JP2001002588A (de)
KR (1) KR20010029770A (de)
AT (1) ATE269698T1 (de)
AU (1) AU3781000A (de)
CA (1) CA2310272A1 (de)
CO (1) CO5170459A1 (de)
DE (1) DE60011710T2 (de)
DK (1) DK1057480T3 (de)
ES (1) ES2220346T3 (de)
HU (1) HUP0002085A3 (de)
IL (1) IL136376A0 (de)
NZ (1) NZ504868A (de)
PE (1) PE20010207A1 (de)
PT (1) PT1057480E (de)
ZA (1) ZA200002693B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5271709A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
AU785199B2 (en) * 2000-06-01 2006-11-02 Watson Pharmaceuticals, Inc. Transdermal delivery of lasofoxifene
US9510946B2 (en) 2012-09-06 2016-12-06 Edwards Lifesciences Corporation Heart valve sealing devices

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US6034102A (en) * 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis

Also Published As

Publication number Publication date
EP1057480A2 (de) 2000-12-06
JP2001002588A (ja) 2001-01-09
PE20010207A1 (es) 2001-02-28
AU3781000A (en) 2000-12-07
DE60011710D1 (de) 2004-07-29
ZA200002693B (en) 2001-11-30
CA2310272A1 (en) 2000-12-01
DK1057480T3 (da) 2004-11-08
ATE269698T1 (de) 2004-07-15
KR20010029770A (ko) 2001-04-16
EP1057480A3 (de) 2002-01-09
EP1057480B1 (de) 2004-06-23
DE60011710T2 (de) 2005-06-30
CO5170459A1 (es) 2002-06-27
HUP0002085A2 (en) 2001-03-28
PT1057480E (pt) 2004-10-29
HU0002085D0 (en) 2000-08-28
ES2220346T3 (es) 2004-12-16
HUP0002085A3 (en) 2002-09-30
NZ504868A (en) 2001-09-28

Similar Documents

Publication Publication Date Title
GR3035774T3 (en) Substituted benzolactam compounds as substance p antagonists
GB2364725B (en) Method for treatment of underground reservoirs
GB9915354D0 (en) Method for treatment of underground reservoirs
HUP0105036A3 (en) Imidazo-quinolin derivatives for treating sexual disturbances
EP1077704A4 (de) Kombinationstherapie zur behandlung der depression
AU2002210462A1 (en) Transdermal therapeutic system for treating restless-legs-syndrome
SI1176964T1 (sl) Uporaba et743 za zdravljenje raka
NZ513697A (en) Method for treating exercise induced asthma
PL350167A1 (en) Medicament for treating hypertension
GB9815618D0 (en) Treatment of dyskinesia
HU0002509D0 (en) Combination therapy for treatment of migraine
AU1392101A (en) Method of treating a textile
HU0002085D0 (en) Transdermal estrogen agonist-antagonist therapy
ZA9810215B (en) 2-Aryl-3-Aroylbenzo[b]thiophenes useful for the treatment of estrogen deprivation syndrome.
NZ308516A (en) Transdermal therapeutic system (tts) for administering testosterone
IL148166A0 (en) Drug for treating fractures
HU0002508D0 (en) Combination therapy for treatment of migraine
GB2332849B (en) Apparatus for the treatment of soil
MXPA04004844A (es) Tratamiento de hipertonia durante la fase aguda de un accidente cerebrobascular.
GB2350998B (en) Roller support for grass treatment machine
FI990127A0 (fi) Menetelmä massan käsittelemiseksi
HUP0105152A3 (en) Method for treatment of headache
PL350354A1 (en) Dibenzoazulene derivatives for treating thrombosis, osteoporosis, arteriosclerosis
IL136024A0 (en) Combination therapy for the treatment of migraine
HUP0003191A3 (en) Machine for heat treatment of soils